Table of Contents
Chemotherapy Research and Practice
Volume 2015, Article ID 316015, 16 pages
http://dx.doi.org/10.1155/2015/316015
Review Article

Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers

Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA

Received 3 May 2015; Revised 22 July 2015; Accepted 3 August 2015

Academic Editor: G. J. Peters

Copyright © 2015 Matthew Trendowski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Sonodynamic therapy (SDT) is a form of ultrasound therapy in which specialized chemotherapeutic agents known as sonosensitizers are administered to increase the efficacy of ultrasound-mediated preferential damage of neoplastic cells. Multiple in vitro and in vivo studies have indicated that SDT has the ability to exhibit profound physical and chemical changes on cellular structure. As supportive as the data have been, assessment of this method at the clinical level has been limited to only solid tumors. Although SDT has shown efficacy against multiple adherent neoplastic cell lines, it has also shown particular promise with leukemia-derived cell lines. Potential procedures to administer SDT to leukemia patients are heating the appendages as ultrasound is applied to these areas (Heat and Treat), using an ultrasound probe to scan the body for malignant growths (Target and Destroy), and extracorporeal blood sonication (EBS) through dialysis. Each method offers a unique set of benefits and concerns that will need to be evaluated in preclinical mammalian models of malignancy before clinical examination can be considered.